32 citations,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
10 citations,
October 2010 in “Hepatology” Certain liver diseases respond well to specific treatments and have varying risks for liver cancer.
15 citations,
January 2014 in “Dermatology” Some patients treated with peginterferon and ribavirin for chronic hepatitis C had mild to moderate skin reactions, but treatment did not need to be stopped.
2 citations,
January 2007 in “Acta Dermato Venereologica” A patient developed a blister at the injection site after hepatitis C treatment.
52 citations,
October 2010 in “Antiviral Therapy” New treatments for Hepatitis C show promise but need more research to confirm their safety and effectiveness for clinical use.